Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.12.2014 | special report | Ausgabe 4/2014

memo - Magazine of European Medical Oncology 4/2014

Towards automation of flow cytometric analysis for quality-assured follow-up assessment to guide curative therapy for acute lymphoblastic leukaemia in children

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 4/2014
Autoren:
Michael Reiter, Jana Hoffmann, Florian Kleber, Angela Schumich, Gerald Peter, Florian Kromp, Martin Kampel, Michael Dworzak
Wichtige Hinweise
For machine-learning issues, please contact Michael Reiter, and for clinical issues, please contact Michael Dworzak.

Abstract

Minimal residual disease (MRD) is of high prognostic value in risk stratification in childhood acute lymphoblastic leukaemia. Flow cytometry (FCM) was shown to yield reliable results in MRD measurement. However, the interpretation of FCM data relies largely on operator skills and experience. While sample preparation, antibody panels, staining procedures and flow cytometric acquisition can be standardized, easily controlled and be made available worldwide, the availability of experienced operators represents the current bottleneck to a growing number of laboratories to the benefit of an increasing number of patients with leukaemia. Currently, international paediatric studies—throughout Europe, South America, to Australia—aim at stratifying the treatment according to the FCM-MRD methodology. The measurements are still operator-dependent leading to substantial costs regarding training and quality control. This article introduces a new European Union-funded project (AutoFLOW) aiming at the standardization and automation of FCM-MRD analysis by machine-learning technology.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2014

memo - Magazine of European Medical Oncology 4/2014 Zur Ausgabe

editorial

Angiogenesis